<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621811</url>
  </required_header>
  <id_info>
    <org_study_id>NAT-19/GPX</org_study_id>
    <nct_id>NCT05621811</nct_id>
  </id_info>
  <brief_title>Different Doses of Naronapride vs. Placebo in Gastroparesis</brief_title>
  <acronym>MOVE-IT</acronym>
  <official_title>Double-blind, Randomised, Placebo-controlled, Dose-finding Phase IIb Trial to Evaluate the Efficacy, Safety, and Tolerability of a 12-week-treatment With Naronapride in Adult Participants With at Least Moderate Idiopathic or Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II&#xD;
      dose-finding trial. The trial will be conducted with four treatment groups in the form of a&#xD;
      parallel group comparison and will serve to compare oral treatment with daily doses of 10,&#xD;
      20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2023</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary total score from baseline to week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Naronapride 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naronapride 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naronapride 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naronapride</intervention_name>
    <description>Naronapride is a 5HT-4 agonist</description>
    <arm_group_label>Naronapride 10 mg</arm_group_label>
    <arm_group_label>Naronapride 20 mg</arm_group_label>
    <arm_group_label>Naronapride 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women between ≥18 and ≤75 years of age&#xD;
&#xD;
          -  History of idiopathic or diabetic gastroparesis cardinal symptoms for ≥3 months&#xD;
&#xD;
          -  Evidence of delayed gastric emptying&#xD;
&#xD;
          -  Average weekly total symptom score of ≥2.0&#xD;
&#xD;
          -  Body Mass Index ≥16 and &lt;35 kg/m2&#xD;
&#xD;
          -  Exclusion of any mechanical and/or anatomical obstructions, stenosis, structural&#xD;
             diseases, or gastric ulcers by upper gastrointestinal endoscopy/an imaging technique&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants without access to an internet-capable terminal and/or without an own&#xD;
             e-mail address&#xD;
&#xD;
          -  History of major gastrointestinal surgery&#xD;
&#xD;
          -  Intrapyloric botulinum toxin injection within 12 months&#xD;
&#xD;
          -  Gastric stimulator implant&#xD;
&#xD;
          -  Known secondary causes of gastroparesis&#xD;
&#xD;
          -  Presence of inflammatory bowel disease, eosinophilic oesophagitis, or reflux&#xD;
             oesophagitis, acute gastritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Tack</last_name>
      <phone>3216344225</phone>
      <email>jan.tack@kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>February 1, 2023</last_update_submitted>
  <last_update_submitted_qc>February 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stomach</keyword>
  <keyword>diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ATI 7505</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

